neladalkib

News

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.